ProfileGDS5678 / 1423594_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 70% 70% 71% 55% 69% 51% 49% 57% 62% 76% 75% 69% 72% 69% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.3731170
GSM967853U87-EV human glioblastoma xenograft - Control 24.382770
GSM967854U87-EV human glioblastoma xenograft - Control 34.4949971
GSM967855U87-EV human glioblastoma xenograft - Control 43.336155
GSM967856U87-EV human glioblastoma xenograft - Control 54.2830869
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3300651
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2552749
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4413257
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.677862
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.0864576
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.0027675
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.2250169
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.5666772
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.2612169